VJHemOnc is committed to improving our service to you

EBMT 2020 | CD3 x CD33 bispecific antibodies redirect donor T-cells against HLA loss

VJHemOnc is committed to improving our service to you

Pier Edoardo Rovatti and Pier Edoardo Rovatti

Pier Edoardo Rovatti, MD, IRCCS San Raffaele Scientific Institute, Milan, Italy, outlines the ability of anti CD3 x CD33 bispecific antibodies to redirect donor T-cells against HLA loss in leukemia relapses. Dr Rovatti discusses how anti-CD3 x CD33 bispecific antibodies can effectively redirect donor T-cells against HLA loss leukemia variants which is results in their rapid killing. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter